Date: 2013-06-25
Type of information: Private placement
Company: MDxHealth (Belgium)
Investors: Valiance Asset Management (UK) Biovest Comm
Amount: €18 Million
Funding type: private placement of new shares
Planned used: The net proceeds of the private placement will be used to support and scale-up the Company\'s U.S.-based CLIA-registered commercial laboratory, its US-based sales and marketing efforts, European and global commercial efforts for its Clinical Molecular Diagnostics (ClinicalMDx) and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions and services to clinicians and pharmaceutical customers, and to accelerate proprietary product development.
Others: * On June 25, 2013, MDxHealth, a Belgian molecular diagnostics company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, has announced that it successfully raised an aggregate amount of €18 million in a private placement through the issuance of 8,737,683 new shares at a subscription price of € 2.06 per share (which represents the average closing price of the company\'s shares during the 30 preceding calendar days). Certain funds managed by Valiance Asset Management Ltd participated in the private placement for a total amount of 4,368,932 new shares and Biovest Comm. VA, the investment company of Rudi Mariën, participated in the private placement for a total amount of 2,427,184 new shares. The remaining 1,941,747 new shares were underwritten by Petercam who acted as sole lead manager in the transaction, and will be placed with a limited group of investors.
The 1,941,747 new shares underwritten by Petercam with the view to be placed with investors are expected to be admitted to listing on NYSE Euronext Brussels immediately following their issuance. The other new shares are expected to be listed in the near future following the approval and publication of a listing prospectus.
Therapeutic area: Diagnostic - Cancer - Oncology
